IndraLab
Statements
Empagliflozin inhibits NLRP3. 28 / 28
|
1
27
reach
"As a hypoglycemic agent, in addition to lowering blood sugar and reducing the incidence of cardiovascular events in diabetic patients, empagliflozin was also reported to inhibit the activation of the NLRP3 inflammasome, thus reducing cardiac inflammation and preserving cardiac function via a Ca -dependent mechanism (131)."
reach
"11 An in vitro study pointed out that empagliflozin exerts an antioxidant effect in cardiac myocytes by decreasing Dox-induced lipid peroxidation in cardiac myocytes.10 Besides, Quagliariello et al. discovered in vivo that empagliflozin inhibited inflammation, apoptosis, fibrosis, and ferroptosis in Dox-induced mice via the NLRP3- and MyD88-related pathways, thereby greatly improving cardiac functions.12 Hence, it could be concluded from the above that empagliflozin may have the effect of alleviating Dox-induced cardiotoxicity."
reach
"Of note, empagliflozin attenuated activation of the NLRP3 inflammasome and expression of associated markers of sterile inflammation in hearts from mice with HFrEF, implicating reduced cardiac inflammation as a mechanism of empagliflozin that contributes to sustained function in HFrEF in the absence of diabetes mellitus."